The Immune System Effects of Cannabinoids Should Be Considered With Every Prescription | Research

The takeaway

A review argued that both cannabinoid receptor agonists and antagonists have significant immune effects that are relevant to the conditions they treat and should be factored into prescribing decisions.

Read this if you prescribe or use cannabinoid medicines and want to understand their immune system effects.

Both cannabinoid agonists and antagonists have significant immune effects relevant to their therapeutic uses

What the researchers found

This review examined the immunological effects of cannabinoids in the context of their clinical applications.

Both endogenous and exogenous cannabinoids were shown to be "potently immunoactive." The review argued that these immune effects are not incidental side effects but are highly relevant to the conditions for which cannabinoid therapeutics are prescribed.

For cannabinoid receptor agonists (used for pain, nausea, appetite, spasticity), immunosuppressive effects could be beneficial in inflammatory conditions but harmful in infections or cancer.

For CB1 receptor antagonists (developed for obesity), immune activation could either help or harm depending on the patient's immune status.

The central argument was that immunological effects should be considered with each prescribing decision, not treated as secondary concerns.

Why it matters

As cannabinoid medicines become more widely prescribed, understanding their immune effects is essential. Immunosuppression could worsen outcomes in patients with infections or cancer, while it might benefit those with autoimmune conditions.

The numbers in context

Both CB1 and CB2 receptor signaling have documented immunological effects. Agonists tend to be immunosuppressive. Antagonists can have immune-activating effects.

How the study worked

Narrative review synthesizing evidence on immunological effects of cannabinoid receptor agonists and antagonists, organized by therapeutic application.

What this study cannot tell us

Narrative review without systematic methodology. Much of the immunological evidence was preclinical. The clinical significance of cannabinoid immune effects in typical prescribing scenarios was not always clear.

How to read the evidence

Narrative review raising an important clinical consideration. Evidence is primarily preclinical with limited clinical validation.

When this study was published

Published in 2010. Cannabinoid immunology has continued to develop, with increasing attention to immune effects in clinical settings.

The bigger picture

The immune effects of cannabinoids add another dimension to the risk-benefit analysis of cannabinoid medicines. As more conditions are treated with cannabinoid-based therapies, personalized assessment of immune status becomes increasingly important.

Questions still open

Should patients receiving cannabinoid medicines be monitored for immune changes? Could immunomodulatory effects be exploited therapeutically in autoimmune diseases? Do different cannabinoids have different immune profiles?

Common questions

Does cannabis suppress the immune system?

Cannabinoid receptor agonists (including THC) tend to have immunosuppressive effects. Whether this is clinically meaningful depends on dose, duration, and the individual's health status. People with compromised immune systems may need to be more cautious.

Could immune suppression ever be beneficial?

Yes, in conditions where the immune system is overactive (autoimmune diseases, chronic inflammation), the immunosuppressive properties of cannabinoids could potentially be therapeutic. This is an active area of research.

Read the original research

Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.

International immunopharmacology, 10(5), 547-55

View on PubMed ↗Publisher’s paper ↗

Citation

Greineisen, William E; Turner, Helen. (2010). Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.. International immunopharmacology, 10(5), 547-55. https://doi.org/10.1016/j.intimp.2010.02.012